M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition PharmaphorumIpsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.HematologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) Pharmaphorum Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca receives CHMP positive opinion for CLL in EuropeNext: Viridian wins FDA approval for Lumvoa for thyroid eye disease Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026